Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.70 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.70 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.70 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.52 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841611 | 1.00 | LPAR3 (0.70) | LPAR3LPAR2LPAR1BTN3A1LPAR5 | |
| SCHEMBL6820795 | 1.00 | LPAR3 (0.70) | LPAR3LPAR2LPAR1BTN3A1LPAR5 | |
| SCHEMBL3629460 | 1.00 | LPAR3 (0.70) | LPAR3LPAR2LPAR1BTN3A1LPAR5 | |
| SCHEMBL31174504 | 1.00 | LPAR3 (0.70) | LPAR3LPAR2LPAR1BTN3A1LPAR5 | |
| SCHEMBL7850798 | 1.00 | LPAR3 (0.70) | LPAR3LPAR2LPAR1BTN3A1LPAR5 | |
| SCHEMBL6253419 | 1.00 | LPAR3 (0.70) | LPAR3LPAR2LPAR1BTN3A1LPAR5 | |
| SCHEMBL2858464 | 1.00 | LPAR3 (0.70) | LPAR3LPAR2LPAR1BTN3A1LPAR5 | |
| SCHEMBL2868942 | 1.00 | LPAR3 (0.70) | LPAR3LPAR2LPAR1BTN3A1LPAR5 | |
| SCHEMBL2871266 | 1.00 | LPAR3 (0.70) | LPAR3LPAR2LPAR1BTN3A1LPAR5 | |
| SCHEMBL1903474 | 1.00 | LPAR3 (0.70) | LPAR3LPAR2LPAR1BTN3A1LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107709555-A | The unidirectional of synthesis for the gene editing of Cas9 mediations leads RNA | 达尔马科恩有限公司 | 2018-02-16 | — | — | CN | claimed |
| CN-110525079-A | Ink jet printing method | OMYA INT AG | 2019-12-03 | — | — | CN | disclosed |
| CN-105051057-B | Cellular responsibility, long-acting or targeting compstatin analogs and compositions related and method | 阿佩利斯制药公司 | 2019-11-19 | — | — | CN | disclosed |
| CN-106459969-B | Compositions and methods for modulating growth hormone receptor expression | IONIS制药公司 | 2019-11-15 | — | — | CN | disclosed |
| CN-107428189-B | Ink jet printing method | 欧米亚国际集团 | 2019-11-12 | — | — | CN | disclosed |
| CN-110446789-A | Synthetic muitistates for muitistate determination | CELLULAR RES INC | 2019-11-12 | — | — | CN | disclosed |
| CN-110418647-A | The nucleic acid modifying enzyme and its application method of RNA guidance | UNIV CALIFORNIA | 2019-11-05 | — | — | CN | disclosed |
| CN-110382708-A | SELECTIVE AMPLIFICATION USING BLOCKING OLIGONUCLEOTIDES | 赛卢拉研究公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-110249053-A | COMBINATION THERAPY FOR C3 INHIBITION | 阿佩利斯制药有限公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-110234326-A | Compositions and methods for inhibiting factor XII gene expression | 箭头药业股份有限公司 | 2019-09-13 | — | — | CN | disclosed |
| CN-101410406-B | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS INC | 2012-06-20 | — | — | CN | disclosed |
| CN-102026672-A | C2ORF18 as target gene for cancer therapy and diagnosis | ONCOTHERAPY SCIENCE INC | 2011-04-20 | — | — | CN | disclosed |
| US-7858661-B2 | Protein refolding agent and refolding method | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20100168403-A1 | Protein refolding agent and refolding method | YAMAGUCHI SHUNICHLRO | 2010-07-01 | — | — | US | disclosed |
| CN-101495654-A | Reagents, methods, and libraries for gel-free bead-based sequencing | APPLERA CORP (US) | 2009-07-29 | — | — | CN | disclosed |
| US-20090111971-A1 | PROTEIN REFOLDING AGENT AND REFOLDING METHOD | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| CN-101189345-A | Reagents, methods, and libraries for bead-based sequencing | AGENCOURT BIOSCIENCE CORP (US) | 2008-05-28 | — | — | CN | disclosed |
| CN-1348376-A | Method for validating/invalidating target(s) and pathways | EPIGENESIS PHARMACEUTICALS INC (US) | 2002-05-08 | — | — | CN | disclosed |
| CN-1230226-A | Sequencing by ligation of encoded adaptors | LYNX THERAPEUTICS INC (US) | 1999-09-29 | — | — | CN | disclosed |
| CN-1170367-A | Down-regulation of gene expression using 2' -substituted oligonucleotides | HYBRIDON INC (US) | 1998-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111971-A1 | PROTEIN REFOLDING AGENT AND REFOLDING METHOD | HSPA5, HSPBP1, RRBP1 | LPAR3 3912/4885LPAR2 3384/4885LPAR1 3372/4885 |
| US-20100168403-A1 | Protein refolding agent and refolding method | HSPA5, HSPBP1, RRBP1 | LPAR3 3796/4885LPAR2 3321/4885LPAR1 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.